In the first quarter of this year, global private equity exit volume decreased, but aggregate transaction value surged thanks to Elon Musk's record-setting $250 billion deal between SpaceX and xAI. This merger, which made up about 80% of the total transaction value for the quarter, redefined global M&A, surpassing Vodafone's 2000 acquisition of Mannesmann. The IPO market, however, remained challenging despite a gradual recovery in 2025.

AbbVie announced an expanded partnership with BioLabs, becoming the founding sponsor of the new BioLabs University of Toronto. This collaboration aims to accelerate life science research and foster innovation in Canada's biotech sector, including providing laboratory space and mentorship to early-stage startups. The initiative supports the Ontario Life Sciences Strategy and strengthens the region's position as a biomanufacturing and life sciences hub.

A recent Lobbying Disclosure Act filing revealed that Humana Inc. disclosed $2,550,000 in lobbying expenses for Q1 2026, targeting issues such as Medicare Advantage, Part D, Medicaid, and pharmacy benefit managers. The report also highlights recent congressional stock trading, insider purchases, and significant institutional investor activity related to HUM stock. Wall Street analysts have issued mostly "Buy" ratings and price targets, with a median target of $195.0.

A recent Lobbying Disclosure Act filing revealed that MERCK & CO INC (MRK) disclosed $4,150,000 in lobbying expenditures for Q1 2026, targeting issues such as the Pharmacy Benefit Manager Reform Act, drug pricing, and various appropriations legislations. The article also details recent congressional and insider trading activity in MRK stock, as well as hedge fund movements and analyst ratings, indicating a mix of institutional interest and continued insider sales.

A recent Lobbying Disclosure Act filing for Q1 2026 revealed that Microsoft Corporation spent $2,390,000 on lobbying efforts. The lobbying focused on a wide array of issues including licensing, competition, trade, government procurement, health IT, cybersecurity policies, AI legislation, privacy, education, and various tax and trade matters. The article also provides details on congressional stock trading, insider trading activity, hedge fund movements, and analyst ratings for Microsoft.

Boeing has disclosed $2,450,000 in lobbying expenditures for Q1 2026, covering a broad range of issues from appropriations acts and environmental regulations to international trade and healthcare. Additionally, the article details recent congressional and insider trading activity in BA stock, as well as significant hedge fund movements and analyst ratings, with a median price target of $272.5.

Bank of America Corporation (BAC) recently disclosed $1,680,000 in lobbying expenditures for Q1 2026, targeting issues such as cybercrime, regulatory capital, deposit insurance reform, renewable energy tax credits, and digital asset regulations. The article also details recent congressional stock trading, insider trading activity with significant sales, and changes in institutional investor holdings for BAC. Analyst ratings remain largely positive, with a median price target of $61.0 from 15 analysts.

Gilead Sciences Inc. has disclosed $3,190,000 in lobbying expenditures for Q1 2026, focusing on drug pricing, intellectual property, global supply chain, and various health-related legislative acts. The company also saw significant insider selling activity, with Chairman & CEO Daniel Patrick O'Day selling over $40 million in shares, and mixed hedge fund activity. Wall Street analysts maintain a positive outlook, with six firms issuing "Buy" ratings and a median price target of $155.0.

HCA Healthcare Inc. recently disclosed $1,810,000 in lobbying expenditures for Q1 2026, focusing on healthcare legislation. The article also details significant insider stock sales ($28.3 million) and institutional investor activity, with some major firms decreasing positions while others increased. Analyst ratings for HCA are predominantly positive, with a median price target of $550.5.

A recent lobbying disclosure revealed that GENERAL ELECTRIC COMPANY (INCLUDING SUBSIDIARIES) spent $1,500,000 in lobbying during Q1 2025, addressing issues from NASA appropriations to defense programs and trade policies. The report also highlights recent trading activity of GE stock by members of Congress and company insiders, as well as significant institutional investor movements and analyst ratings with a median price target of $351.5.